Opus Genetics, Inc. (IRD) - Total Assets
Based on the latest financial reports, Opus Genetics, Inc. (IRD) holds total assets worth $50.24 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore how well can Opus Genetics, Inc. service its debt to assess how comfortably operating cash covers total debt obligations.
Opus Genetics, Inc. - Total Assets Trend (2019–2025)
This chart illustrates how Opus Genetics, Inc.'s total assets have evolved over time, based on quarterly financial data. See Opus Genetics, Inc. (IRD) net assets for net asset value and shareholders' equity analysis.
Opus Genetics, Inc. - Asset Composition Analysis
Current Asset Composition (December 2025)
Opus Genetics, Inc.'s total assets of $50.24 Million consist of 99.6% current assets and 0.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 89.8% |
| Accounts Receivable | $3.17 Million | 6.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Opus Genetics, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Opus Genetics, Inc. (IRD) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Opus Genetics, Inc.'s current assets represent 99.6% of total assets in 2025, an increase from 98.8% in 2019.
- Cash Position: Cash and equivalents constituted 89.8% of total assets in 2025, up from 86.2% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 6.3% of total assets.
Opus Genetics, Inc. Competitors by Total Assets
Key competitors of Opus Genetics, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Opus Genetics, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.43 | 3.24 | 5.24 |
| Quick Ratio | 6.43 | 3.24 | 5.24 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $42.26 Million | $25.32 Million | $9.80 Million |
Opus Genetics, Inc. - Advanced Valuation Insights
This section examines the relationship between Opus Genetics, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 24.28 |
| Latest Market Cap to Assets Ratio | 5.27 |
| Asset Growth Rate (YoY) | 36.3% |
| Total Assets | $50.24 Million |
| Market Capitalization | $264.90 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Opus Genetics, Inc.'s assets at a significant premium (5.27x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Opus Genetics, Inc.'s assets grew by 36.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Opus Genetics, Inc. (2019–2025)
The table below shows the annual total assets of Opus Genetics, Inc. from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $50.24 Million | +36.30% |
| 2024-12-31 | $36.86 Million | -31.67% |
| 2023-12-31 | $53.95 Million | +10.12% |
| 2022-12-31 | $48.99 Million | +87.87% |
| 2021-12-31 | $26.08 Million | +47.48% |
| 2020-12-31 | $17.68 Million | +891.14% |
| 2019-12-31 | $1.78 Million | -- |
About Opus Genetics, Inc.
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 t… Read more